Business Context and Reporting Period
Company: Entero Therapeutics, Inc. (formerly First Wave Biopharma, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Entero is a clinical-stage biopharmaceutical company focused on developing non-systemic therapies for gastrointestinal diseases. Its primary asset is Adrulipase, a recombinant lipase enzyme for cystic fibrosis and chronic pancreatitis. The company recently terminated its Capeserod license with Sanofi and is actively pursuing the disposal of its ImmunogenX (IMGX) subsidiary, which holds the Latiglutenase and CypCel assets.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,257,890) | $(998,271) |
| Net Loss Applicable to Common Shareholders | $(2,421,318) | $(1,080,436) |
| Loss Per Share (Basic & Diluted) | $(0.51) | $(0.21) |
| Cash and Cash Equivalents (Ending) | $4,474 | $4,474 |
| Total Debt (Current) | $700,000 (Revolving Line of Credit) | $700,000 |
| Accumulated Deficit | $(204,645,898) | $(204,645,898) |
| Stockholders' Equity (Deficit) | $(6,298,054) | $(6,298,054) |
Note: The company has no revenue. Significant assets ($83.2M) and liabilities ($23.5M) related to the IMGX subsidiary are classified as "held-for-sale" and reported as discontinued operations.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased significantly to $1.46 million for the six months ended June 30, 2025, compared to $12.53 million in the prior year period. This 88% reduction is primarily due to the absence of non-cash expenses related to the IMGX merger (financial advisor fees) and reduced headcount.
- Discontinued Operations: Loss from discontinued operations (IMGX) was $0.63 million for the six months ended June 30, 2025, compared to $1.32 million in the prior year.
- Liquidity: Cash and cash equivalents dropped from $163,476 at year-end 2024 to $4,474 at June 30, 2025, reflecting a net cash burn of $173,513 for the period.
- Debt: The company drew $700,000 on a new revolving line of credit in January 2025. Interest on this facility is 18% per annum.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance. With only ~$4,500 in cash and an accumulated deficit of $204.6 million, the company requires immediate additional funding to continue operations.
Strategic Developments
- IMGX Rescission: The company entered a Rescission Agreement to unwind the 2024 acquisition of ImmunogenX. The transaction is expected to close by September 30, 2025, returning IMGX assets and liabilities to former shareholders, though Entero will retain ~$695,000 of IMGX accounts payable.
- Program Termination: The license for Capeserod was terminated in February 2025 with no further payments due. The Latiglutenase and Niclosamide programs are being discontinued or sold.
- Capital Raise: On August 9, 2025 (subsequent event), the company entered a Securities Purchase Agreement for gross proceeds of approximately $3.0 million via pre-funded warrants and common warrants.
Risks and Contingencies
- Nasdaq Compliance: The company received an extension until October 8, 2025, to regain compliance with the minimum stockholders' equity requirement ($2.5M). It regained compliance with the annual meeting requirement in July 2025.
- Legal Proceedings:
- Mattress Liquidators: A lawsuit regarding a $7.9M loan to IMGX was settled in April 2025. Guarantors paid $5.5M; IMGX remains responsible for the remaining debt and legal fees. Entero expects no further liability upon closing the Rescission Agreement.
- Ellenoff Grossman & Schole (EGS): Law firm sued for unpaid legal fees of ~$749,300. The company is negotiating a settlement.
- Lease Default: The company defaulted on its Boca Raton headquarters lease in March 2025, resulting in a $108,759 impairment of the Right-of-Use asset.
Investor Verification Checklist
- Cash Runway: Verify the closing of the $3.0 million August 2025 financing and the sufficiency of funds to cover operating expenses beyond the current quarter.
- IMGX Rescission Closing: Confirm the consummation of the Rescission Agreement by September 30, 2025, to ensure the transfer of IMGX liabilities (including the $9.3M secured debt) away from Entero.
- Nasdaq Status: Monitor compliance with the minimum stockholders' equity requirement deadline of October 8, 2025.
- Legal Settlements: Track the resolution of the EGS lawsuit regarding unpaid legal fees.
- Debt Covenants: Review the terms of the 18% revolving credit facility and any conditions related to the "Qualified Public Equity Offering" required by the lender.